Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer.

Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE, Mirnezami AH.

Cancer Lett. 2018 Apr 28;420:228-235. doi: 10.1016/j.canlet.2018.02.002. Epub 2018 Feb 7. Review.

2.

Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression.

Bhome R, Goh RW, Bullock MD, Pillar N, Thirdborough SM, Mellone M, Mirnezami R, Galea D, Veselkov K, Gu Q, Underwood TJ, Primrose JN, De Wever O, Shomron N, Sayan AE, Mirnezami AH.

Aging (Albany NY). 2017 Dec 28;9(12):2666-2694. doi: 10.18632/aging.101355.

3.

Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications.

Giza DE, Fuentes-Mattei E, Bullock MD, Tudor S, Goblirsch MJ, Fabbri M, Lupu F, Yeung SJ, Vasilescu C, Calin GA.

Cell Death Differ. 2016 Dec;23(12):1906-1918. doi: 10.1038/cdd.2016.94. Epub 2016 Oct 14. Review.

4.

Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.

Bhome R, Al Saihati HA, Goh RW, Bullock MD, Primrose JN, Thomas GJ, Sayan AE, Mirnezami AH.

New Horiz Transl Med. 2016 Jan;3(1):9-21.

5.

The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.

Troppan KT, Melchardt T, Wenzl K, Schlick K, Deutsch A, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Tränkenschuh W, Greil R, Neumeister P, Egle A, Pichler M.

J Clin Pathol. 2016 Apr;69(4):326-30. doi: 10.1136/jclinpath-2015-203356. Epub 2015 Dec 7.

PMID:
26644520
6.

MicroRNAs in Testicular Cancer Diagnosis and Prognosis.

Ling H, Krassnig L, Bullock MD, Pichler M.

Urol Clin North Am. 2016 Feb;43(1):127-34. doi: 10.1016/j.ucl.2015.08.013. Review.

PMID:
26614035
7.

Long Non-Coding RNAs in Endometrial Carcinoma.

Smolle MA, Bullock MD, Ling H, Pichler M, Haybaeck J.

Int J Mol Sci. 2015 Nov 4;16(11):26463-72. doi: 10.3390/ijms161125962. Review.

8.

Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.

Stotz M, Gerger A, Haybaeck J, Kiesslich T, Bullock MD, Pichler M.

Anticancer Res. 2015 Nov;35(11):5737-44. Review.

PMID:
26503994
9.

Estrogen and breast cancer: can less mean more?

Bullock MD, Silva AM, Calin GA.

Cell Cycle. 2015;14(14):2197-8. doi: 10.1080/15384101.2015.1056617. Epub 2015 Jun 19. No abstract available.

10.

A top-down view of the tumor microenvironment: structure, cells and signaling.

Bhome R, Bullock MD, Al Saihati HA, Goh RW, Primrose JN, Sayan AE, Mirnezami AH.

Front Cell Dev Biol. 2015 May 29;3:33. doi: 10.3389/fcell.2015.00033. eCollection 2015. Review.

11.

Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer.

Bullock MD, Silva AM, Kanlikilicer-Unaldi P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA.

Noncoding RNA. 2015 Jun 3;1(1):53-68. doi: 10.3390/ncrna1010053. Review.

12.

Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.

Bullock MD, Pickard K, Mitter R, Sayan AE, Primrose JN, Ivan C, Calin GA, Thomas GJ, Packham GK, Mirnezami AH.

Oncotarget. 2015 Mar 30;6(9):7262-79.

13.

The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.

Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Egle A, Pichler M.

Eur J Haematol. 2015 Dec;95(6):538-44. doi: 10.1111/ejh.12529. Epub 2015 Mar 26.

PMID:
25677782
14.

Molecular profiling of the invasive tumor microenvironment in a 3-dimensional model of colorectal cancer cells and ex vivo fibroblasts.

Bullock MD, Mellone M, Pickard KM, Sayan AE, Mitter R, Primrose JN, Packham GK, Thomas G, Mirnezami AH.

J Vis Exp. 2014 Apr 29;(86). doi: 10.3791/51475.

15.

miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.

Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, Thomas GJ, Packham G, Mirnezami AH.

Cancer Res. 2013 Nov 1;73(21):6435-47. doi: 10.1158/0008-5472.CAN-12-3308. Epub 2013 Aug 15.

16.

FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role.

Bullock MD, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, Primrose JN, Ottensmeier C, Packham GK, Thomas G, Mirnezami AH.

Br J Cancer. 2013 Jul 23;109(2):387-94. doi: 10.1038/bjc.2013.355. Epub 2013 Jul 4.

17.

Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.

Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, Mitter R, Primrose JN, Thomas GJ, Packham GK, Mirnezami AH.

Cell Death Dis. 2013 Jun 20;4:e684. doi: 10.1038/cddis.2013.213. Erratum in: Cell Death Dis. 2013;4:e748. Mirenzami, AH [corrected to Mirnezami, AH].

18.

MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression.

Bullock MD, Sayan AE, Packham GK, Mirnezami AH.

Biol Cell. 2012 Jan;104(1):3-12. doi: 10.1111/boc.201100115. Epub 2011 Dec 9. Review.

PMID:
22188537
19.

Intradural extramedullary primary malignant melanoma radiographically mimicking a neurofibroma.

Kanatas AN, Bullock MD, Pal D, Chakrabarty A, Chumas P.

Br J Neurosurg. 2007 Feb;21(1):39-40. Review.

PMID:
17453774

Supplemental Content

Loading ...
Support Center